{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:16:22Z","timestamp":1788308182272,"version":"build-2803163510"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"DOI":"10.1093\/oncolo\/oyag332","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:45:59Z","timestamp":1787139959000},"source":"Crossref","is-referenced-by-count":0,"title":["Perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer: unprecedented outcomes from KEYNOTE-B15"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7194-7873","authenticated-orcid":false,"given":"Sarah","family":"Azari","sequence":"first","affiliation":[{"name":"Department of Urology, University of California San Diego, La Jolla, CA 92093,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirali","family":"Salmasi","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California San Diego, La Jolla, CA 92093,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Diego, La Jolla, CA 92093,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026090119570363900_oyag332-B1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.4111\/icu.20200132","article-title":"Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer","volume":"61","author":"McFerrin","year":"2020","journal-title":"Investig Clin Urol"},{"key":"2026090119570363900_oyag332-B2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.urology.2013.07.072","article-title":"Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database","volume":"83","author":"Zaid","year":"2014","journal-title":"Urology"},{"key":"2026090119570363900_oyag332-B3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2026090119570363900_oyag332-B4","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"key":"2026090119570363900_oyag332-B5","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-Guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"2026090119570363900_oyag332-B6","doi-asserted-by":"publisher","first-page":"TPS579","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS579","article-title":"A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D\u2009+\u2009EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA)","volume":"40(6_suppl)","author":"Powles","year":"2022","journal-title":"JCO"},{"key":"2026090119570363900_oyag332-B7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.eururo.2025.09.003","article-title":"Outcomes with enfortumab vedotin in patients with histologic subtypes of advanced urothelial carcinoma: analysis of the UNITE Study","volume":"90","author":"Jindal","year":"2026","journal-title":"Eur Urol"},{"key":"2026090119570363900_oyag332-B8","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1200\/JCO.2026.44.16_suppl.4508","article-title":"Initial results from NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma","volume":"44(16_suppl)","author":"Iyer","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag332\/70715478\/oyag332.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag332\/70715478\/oyag332.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag332\/70715478\/oyag332.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:57:07Z","timestamp":1788307027000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag332\/8766630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag332","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,6]]},"article-number":"oyag332"}}